Overview

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

Status:
RECRUITING

Trial end date:
2034-08-12

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasis

Phase:

PHASE3

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

deucravacitinib